Aim and background: To assess the efficacy of 2% dorzolamide/0.5% timolol/0.2% brimonidine tartrate fixed combination (DTB-FC) eye drops in patients with intermediate glaucoma stage.
Materials and methods: A retrospective case series study was performed, including eyes diagnosed with primary open-angle (POAG) or chronic angle-closure glaucoma (CACG), which were at intermediate stage of the illness according to the Brusini grading system and were initially treated with 2% dorzolamide/0.5% timolol fixed combination (DT-FC), and switched at baseline to DTB-FC. Main outcome was intraocular pressure (IOP) baseline measured, as well as at weeks 1 and 2, months 1, 3, and 6, and 1 year after switching. IOP differences were analyzed using analysis of variance (ANOVA) repeated measures.
Results: A total of 36 eyes from 22 patients were included in the study. The median age of the participants was 61 years [interquartile range (IQR) 53–71], with 59.1% (n = 13) being female. At baseline, 1, 2 weeks, 1, 3, 6 months, and 1 year after switching to DTB-FC, the mean IOP values were 20.3 (95% CI, 19.5–21.1), 15.3 (95% CI, 14.5–16.1), 15.5 (95% CI, 14.7–16.2), 15.5 (95% CI, 14.8–16.0), 15.5 (95% CI, 14.9–16.2), 15.5 (95% CI, 14.8–16.2) and 15.3 (95% CI, 14.7–15.9) mm Hg, respectively (p > 0.001). The mean IOP reduction after 1 year of treatment was −5.0 ± (4.2–5.8) mm Hg. Treatment success rates were 86.1, 80.6, 80.6, 77.8, 72.2, and 66.7%, respectively. When stratified by diagnosis, there were no statistically significant differences in the treatment success rates between POAG and CACG (p > 0.05).
Conclusion: Therapy switching from DT-FC to DTB-FC was shown to be effective in reducing IOP of eyes with POAG or CACG during 6–12 months.
Clinical significance: The DTB-FC therapy improved the therapeutic management of POAG or CACG previously treated with DT-FC therapy, which may be relevant to prevent its progression in the future.
Quigley H, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90(3):262–267. DOI: 10.1136/bjo.2005.081224
Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014;121(11):2081–2090. DOI: 10.1016/j.ophtha.2014.05.013
Allison K, Patel D, Alabi O. Epidemiology of glaucoma: the past, present, and predictions for the future. Cureus 2020;12(11):e11686. DOI: 10.7759/cureus.11686
Gedde S, Vinod K, Wright MM, et al. Primary open-angle glaucoma preferred practice pattern®. 2020.
Gedde SJ, Vinod K, Wright MM, et al. Primary open-angle glaucoma preferred practice pattern®. Ophthalmology 2021;128(1):71–150. DOI: 10.1016/j.ophtha.2020.10.022
Ambrus A, Lum FC, Garratt S. Primary open-angle glaucoma preferred practice pattern®.
Justiniano MJ. Líneas de tratamiento en glaucoma en ángulo abierto. In: Mundi I, (ed). Glaucoma Tips, Consejos y Experiencias. Santa Cruz de la Sierra; 2022; pp. 172–179.
Konstas AG, Schmetterer L, Katsanos A, et al. Dorzolamide/timolol fixed combination: learning from the past and looking toward the future. Adv Ther 2021;38(1):24–51. DOI: 10.1007/s12325-020-01525-5
Lerner SF, Oddone F, Lu DW, et al. Maximum medical therapy: brinzolamide/brimonidine and travoprost/timolol fixed-dose combinations in glaucoma and ocular hypertension. Clin Ophthalmol 2019;13:2411–2419. DOI: 10.2147/OPTH.S228777
Baiza-Durán LM, Alvarez-Delgado J, Contreras-Rubio AY, et al. The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial. Ann Ophthalmol 2009;41(3–4):174–178. PMID: 20214051.
Baiza-Durán L, Llamas-Moreno J, Ayala-Barajas C. Comparison of timolol 0.5%+brimonidine 0.2%+dorzolamide 2% versus timolol 0.5%+brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2012;6:1051–1055. DOI: 10.2147/OPTH.S33578
Webers CAB, Beckers HJM, Nuijts RMMA, et al. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs and Aging 2008;25(9):729–759. DOI: 10.2165/00002512-200825090-00002
Woodward DF, Chen J. Fixed-combination and emerging glaucoma therapy. Exp Opin Emerg Drugs 2007;12(2):313–328. DOI: 10.1517/14728214.12.2.313
Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs and Aging 2007;24(12):1007–1016. DOI: 10.2165/00002512-200724120-00004
Chen PP. Risk and risk factors for blindness from glaucoma. Curr Opin Ophthalmol 2004;15(2):107–111. DOI: 10.1097/00055735-200404000-00009
Delgado MF, Abdelrahman AM, Terahi M, et al. Management of glaucoma in developing countries: challenges and opportunities for improvement. Clin Outcomes Res 2019;11:591–604. DOI: 10.2147/CEOR.S218277